Journal of Clinical Oncology · 2015 · 45 citations · 0 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyOncology PharmacotherapyMalignant NeoplasmsMolecular Tumor ProfilingTargeted Cancer TherapyTargeted TherapyTyrosine Kinase InhibitorsClinical Trial ReportsExome SequencingHuman Epidermal Growth Factor Receptor 2-Targeted TherapyOncogenic Driver MutationsTargeted Therapy EvaluationTargeted Therapy PharmacologyWhole Exome Sequencing StudiesWhole-exome Sequencing Analysis
2508 Background: FGFR1/2 amplification acts as an oncogenic driver in multiple cancers. We investigated the efficacy of AZD4547, a potent orally available selective inhibitor of FGFR 1,2 & 3 receptor tyrosine kinases, in FGFR1/2 amplified cancers. Methods: This is a phase II Simon 2 stage design for patients (pts) with FGFR1 (HER2 negative breast/NSCLC) or FGFR2 (gastroesophageal) amplified tumors treated with AZD4547 80mg twice daily on an intermittent (2 weeks (wks) on, 1 wk off) or continuous schedule. Eligible pts had progressed following ≥ 1 line of prior therapy. FGFR1/2 amplification was determined centrally using FISH. Primary endpoint is centrally reviewed confirmed response rate (RR), with the study concluding efficacy if ≥ 3/17 patients in a cohort had a confirmed response. PET-CT was performed at baseline, D14 and 8 wks, biopsy at baseline and D14 and optionally on progression. Biomarker assessment included phospho-immunohistochemistry, FGFR copy number variation in tumor and plasma, and whole exome sequencing. Results: We screened 285 pts with advanced cancer, identifying FGFR1 amplification in 18% (20/111) HER2 negative breast cancer (BC), 9.5% (4/42) NSCLC, and FGFR2 amplification in 7.6% (10/132) gastroesophageal (GC). Confirmed RR was 33% (3/9) in FGFR2 amplified GC, and 12.5% (1/8) FGFR1 amplified BC. All 3 GC responders had a PET response on D14 PET. GC responses were durable; time on treatment was 45, 29 and 27 wks with the last pt ongoing. Common toxicities (all grades and schedules) included fatigue (71%), mucositis (41%), nausea (35%), and nail changes (24%). Asymptomatic retinal pigmented epithelial detachment occurred in 1 pt. Phosphate was elevated in most pts. Exploratory analysis revealed all GC pts with PR had FGFR2 FISH ratio > 8. Elevated FGFR2 copy number was detected in free plasma DNA of all GC pts with PR, and no non-responding pt. Analysis of progression biopsies in a responding GC pt identified acquired KRAS amplification in progressing disease. Conclusions: AZD4547 demonstrated high activity in FGFR2 amplified GC and lower activity in FGFR1 amplified BC. Assessment of FGFR2 copy number in cell free plasma DNA may provide a screening tool to identify FGFR2 amplified GC. Clinical trial information: NCT01795768. Clinical trial information: NCT01795768.